Dean Mosca, president of Proprietary Nutritionals, Inc., (PNI) has announced that PNI will assume the exclusive worldwide distribution rights for Sytrinol®, a proprietary, patented formula proven to help lower cholesterol naturally, effective Jan. 1, 2009.
“Sytrinol is derived from citrus bioflavonoids and palm tocotrienols, and was developed after 12 years of research,” said Mosca. “It has been shown to reduce total cholesterol by up to 30% after just 30 days in a recent double-blind, placebo controlled, published study, which compares very favorably to traditional cholesterol lowering drugs.”
Sytrinol was developed by KGK, Synergize, London, ON, and president, Najla Guthrie, said “I’m extremely excited about working with PNI because of their experience and success in bringing scientifically backed ingredients to market.
“The Sytrinol patents and patents pending include the composition of polymethoxylated flavones and tocotrienols in combination with any other heart healthy ingredient such as phytosterols,” said Guthrie. “We are also planning another clinical study on the formula early in the New Year.”
Mosca believes the launch of Sytrinol is well-timed as cardiovascular disease is the number one cause of death in America, according to the American Heart Association.
“Consumers are looking for natural solutions that don’t have the side effects of drugs,” said Mosca. “Studies have shown Sytrinol to be well tolerated, with no toxic side effects.”
Sytrinol will be manufactured by PNI’s parent company, Pharmachem Laboratories, to ensure the consistency and quality of the ingredient.
Proprietary Nutritionals, Inc., a subsidiary of Pharmachem Laboratories, Inc markets a variety of patented, scientifically proven, branded ingredients to the nutrition industry, including Benexia™ Chia Seed, Celadrin® Joint Flexibility & Relief, and the Berry-Max® line of potent berry concentrates, including Cran-Max®, Blue-Max®, Bil-Max®, Elder-Max®, Cherry-Max®, and Pom-Max®. For further information, contact [email protected] .
KGK provides contract research services to the health nutrition, biotechnology and pharmaceutical industries. These services include both pre-clinical and human clinical trials. In addition to its contract research capabilities, KGK has a New Product Development division which brings new and innovative natural health products to the point where they are ready to be manufactured and marketed. These products include Sytrinol® for cardiovascular health, DiabetinolTM for the treatment and/or prevention of Type II Diabetes, and DermytolTM, a new product for the protection of sun damage to the skin.